ENCell files patent for ‘스피드 바카라 platform’ verification model technology for eye disease treatment development

[by Ji, Yong Jun] ENCell, a contract development and manufacturing organization (CDMO) specializing in advanced biopharmaceuticals and new drug development, announced on April 1 that it has completed a patent application with the Korean Intellectual Property Office for its ‘Adeno-Associated Virus (스피드 바카라)’ platform verification model technology, designed for the development of ocular disease treatments.

ENCell is actively developing an 스피드 바카라 platform technology essential for the development of ocular disease treatments, incorporating photoreceptor-specific expression technology in the eye. The company stated that this patent application enables the establishment of an in vitro model for verifying photoreceptor-specific delivery, offering a cost-effective and time-efficient alternative to animal testing while enhancing overall development efficiency.

스피드 바카라 is a gene transfer viral vector system that plays a crucial role in gene therapy due to its low immunogenicity and lack of genome integration. ENCell highlighted its expertise in developing proprietary 스피드 바카라 production technology, emphasizing its competitive advantages in cost reduction and productivity enhancement. The company has achieved these efficiencies through the development of an optimized viral vector production system, strengthening its position in the gene therapy sector.

“Our company is actively developing various platforms to drive innovation in the 스피드 바카라-based therapeutics field while continuously developing related verification models,” an ENCell official said. “We are committed to establishing a leading position in 스피드 바카라-based gene therapy, leveraging our exceptional technological expertise and globally recognized GMP standards.”

Conversely, ENCell aims to strategically expand its 스피드 바카라-based gene therapy sector, leveraging its position as the No. 1 Korean CDMO with the highest track record in multi-product cell gene therapy (CGT) manufacturing and establishing this field as a key growth driver, positioning it as a central pillar in its CDMO expansion strategy.